Students of DOW university claim that they have found the cure of covid-19

Dow University of Health Sciences (DUHS) clinical specialists on Monday asserted that they have made a medication to treat patients experiencing the coronavirus malady.
According to the subtleties, clinical specialists from DUHS asserted that Intravenous Immunoglobulin (IVIG) can fix COVID-19 patients.
Teacher Muhammad Saeed Qureshi, an individual from the exploration group, said that Intravenous Immunoglobulin is an extraordinary improvement in the battle against novel coronavirus.
He said the globulin was produced with cleaned antibodies, acquired from the recuperated coronavirus patients.
"Along these lines of treatment is protected, generally safe and profoundly viable against coronavirus. Through this technique, Immunoglobulin is set up after partition of antibodies found in the blood of a recuperated quiet," the announcement stated, bringing up that this type of treatment has been affirmed by US Food and Drug Administration.
Calling its exertion "a beam of expectation right now emergency", the college included that the examination group, drove by Dr Shaukat Ali, built up this type of treatment after it had the option to gather the principal blood test from a tainted patient in March.
"The group figured out how to confine antibodies from the blood test synthetically, purged it and later focused these antibodies utilizing ultrafiltration strategies that expel the staying undesirable materials from the last item," the announcement included, clarifying the system behind the potential treatment.
The college showed trust in the viability of its treatment by contending that the Covid-19 strain as of now contaminating Pakistanis just has a "couple of changes" and consequently neighborhood IVIG from tainted patients holds the possibility to give an incredibly powerful type of inoculation against Covid-19 for Pakistanis.
A week ago, specialists from the college had found that specific variations of a human quality may offer opposition against the novel coronavirus, otherwise called SARS-CoV-2.
As indicated by their discoveries, which were distributed in the Journal of Medical Virology, two variations of the ACE2 (angiotensin I changing over compound 2) quality — that has been set up as the useful receptor for the novel coronavirus — may make an individual increasingly impervious to the contamination.
On April 9, the Drug Regulatory Authority of Pakistan (DRAP) permitted clinical preliminaries of blood plasma treatment to treat coronavirus patients in the nation.
Plasma, the liquid in blood overflowing with antibodies post-sickness, has just demonstrated successful in little investigations to treat irresistible illnesses including Ebola and SARS.